#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Squamous cell carcinoma of the hypopharynx Neuroendocrine cell hyperplasia of infancy Sarcoma Myelofibrosis Heavy menstrual bleeding Systemic lupus erythematosus Neuroendocrine carcinoma of the skin Follicular lymphoma stage II Chronic graft versus host disease Progressive multifocal leukoencephalopathy Infective uveitis Paget's disease of the vulva Paroxysmal nocturnal haemoglobinuria Skin angiosarcoma Breast cancer More trials…

    Learn about Rare Diseases

    Haemophilia Piriformis syndrome – Trials in Disease Osteosarcoma recurrent – Trials in Disease Cytokine release syndrome – Treatment Adrenocortical carcinoma – Life with Disease Prolymphocytic leukaemia – Diagnostics Osteosarcoma metastatic Lymphatic malformation – Life with Disease Pemphigoid – Diagnostics Sarcoidosis More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Gsk3739937 Vemircopan Iph5201 Betula Pollen Extract Zilovertamab Vedotin Betamethasone Dipropionate Lenvatinib Azelastine [18F]Fluoro-Peg-Folate Ertugliflozin Somapacitan BI 456906 Ng004 MORPHINE H2-Receptor Antagonists Tranexamic Acid Givinostat E.coli Polysaccharide Hydroxocobalamin VX-993 More therapies…

    Learn about Your Condition

    H1N1 influenza Arthritis infective Immunosuppression Constipation Anaemia of chronic disease Left ventricular failure Nephrolithiasis Impaired gastric emptying Breast angiosarcoma Schizoaffective disorder Stargardt's disease Oesophagogastroscopy Cryoglobulinaemia Peripheral spondyloarthritis Metabolic disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • Study on the Effectiveness and Safety of Vibozilimod for Adults with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Vibozilimod
    Estonia Poland

  • Study on Long-Term Safety and Efficacy of Deucravacitinib for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Drugs:
    • Deucravacitinib
    Czechia Finland France Germany Hungary Poland +2

  • Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Bimekizumab
    Germany Poland

  • Study on the Effects of JNJ-81241459 for Patients with Moderate to Severe Psoriasis

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Jnj-81241459
    France Germany Poland Spain

  • Study on Guselkumab for Patients with Moderate-to-Severe Plaque Psoriasis

    Not recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Guselkumab
    Germany

  • Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Brodalumab
    Belgium Czechia France Germany Greece Hungary +3
Previous Page
1 … 5 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!